RPTX

Insider Trades

Name	Value	Action	Price	Current Price
Segal Lloyd MitchellDirector, Officer: PRESIDENT AND CEO $24k21.2k shares SellMar 12, 2025 $1.14 --
Forte SteveEVP, CHIEF FINANCIAL OFFICER $7.8k6.9k shares SellMar 12, 2025 $1.14 --
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICER $6.4k5.6k shares SellMar 12, 2025 $1.14 --
Koehler MariaEVP, CHIEF MEDICAL OFFICER $4.1k3.6k shares SellMar 12, 2025 $1.14 --

Trade RPTX

About Repare Therapeutics Inc.

Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary investigational drug is RP-3500, an oral small molecule inhibitor currently being developed to treat solid tumors that possess specific genomic alterations linked to DNA damage repair. Repare is also advancing RP-6306, which is in Phase I clinical trials for tumors characterized by genetic alterations involving CCNE1 amplification. Furthermore, the company is pursuing a Polymerase Theta program, investigating a synthetic lethal target relevant to BRCA mutations and other genomic abnormalities. Repare Therapeutics Inc. was established in 2016 and maintains its headquarters in Montreal, Canada.

CEO: Steve Forte
IPO Date: Jun 19, 2020

Market Data

Open: $2.65
High: $2.65
Low: $2.65
Volume: 1.2M
Avg Volume: 1.2M
52W High: $2.66
52W Low: $0.89

Valuation

Market Cap: $114M
Enterprise Value: $42M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-76M
Revenue: $53M
Net Income: $-85M
Cash: $85M
Debt: $1.9M

Events

EarningsMar 2

EPS est. -0.29 · actual -0.67